Results 61 to 70 of about 137,029 (384)

Adverse reactions of biological therapies in patients with psoriasis [PDF]

, 2017
Psoriasis is a chronic, immune-mediated disorder characterized by well demarcated, erythematous plaques covered by thick, silvery-white scales, most often located on the knees, elbows, sacral area and scalp.
Georgescu, Simona R., Limbău, Alexandra M., Mitran, Cristina I., Mitran, Mădălina I., Sârbu, Maria I., Tampa, Mircea   +5 more
core   +4 more sources

A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.

JAMA psychiatry, 2013
CONTEXT Increased concentrations of inflammatory biomarkers predict antidepressant nonresponse, and inflammatory cytokines can sabotage and circumvent the mechanisms of action of conventional antidepressants.
C. Raison, R. Rutherford, B. Woolwine, C. Shuo, P. Schettler, D. F. Drake, E. Haroon, Andrew H. Miller   +7 more
semanticscholar   +1 more source

Extracellular Vesicle Biomarkers Reveal Inhibition of Neuroinflammation by Infliximab in Association with Antidepressant Response in Adults with Bipolar Depression

Cells, 2020
Accumulating evidence suggests that neuroinflammation is involved in bipolar disorder (BD) pathogenesis. The tumor necrosis factor-alpha (TNF-α) antagonist infliximab was recently reported to improve depressive symptoms in a subpopulation of individuals ...
R. Mansur, Francheska Delgado-Peraza, Mehala Subramaniapillai, Yena Lee, M. Iacobucci, Nelson B Rodrigues, J. Rosenblat, E. Brietzke, V. Cosgrove, Nicole E. Kramer, T. Suppes, C. Raison, Sahil Chawla, Carlos J Nogueras-Ortiz, R. McIntyre, D. Kapogiannis   +15 more
semanticscholar   +1 more source

Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis

Arthritis Research & Therapy, 2019
Introduction Biosimilar infliximab has the potential for appreciable cost savings compared to its reference biologic, but dose escalation is common and increases costs.
Jeffrey R. Curtis, Fenglong Xie, Jonathan Kay, Joel D Kallich   +3 more
doaj   +1 more source

External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease

Pharmaceutics, 2021
Infliximab is approved for treatment of various chronic inflammatory diseases including inflammatory bowel disease (IBD). However, high variability in infliximab trough levels has been associated with diverse response rates.
Christina Schräpel, Lukas Kovar, Dominik Selzer, Ute Hofmann, Florian Tran, Walter Reinisch, Matthias Schwab, Thorsten Lehr   +7 more
doaj   +1 more source

Use of biological drugs in patients with psoriasis and psoriatic arthritis in italy: Results from the PSONG survey [PDF]

, 2018
This Italian multicenter retrospective study compared the drug survival and efficacy of differentanti-TNF agents in psoriasis (PsO) and psoriatic arthritis (PsA) patients.
Berardesca, E, Bernardini, N, Bianchi, L, Chimenti, S, Costanzo, A., D'Epiro, S, De Simone, C, Narcisi, A, Orsini, D, Peris, K, Potenza, Mc, Richetta, A, Teoli, M, Zangrilli, A   +13 more
core  

Recommendations for the Use of Disease‐Modifying Antirheumatic Drugs in Pregnancy and Reproductive Health for Patients With Rheumatic Disease: A Scoping Review

Arthritis Care &Research, EarlyView.
Objective Autoimmune rheumatic diseases commonly affect individuals of childbearing age, with historically increased adverse pregnancy outcomes in this group. The advent of disease‐modifying antirheumatic drugs (DMARDs) has fostered more suitable conditions for pregnancy; however, this is accompanied by challenges in ensuring safe use in reproductive ...
Athena Chin, Alice Terrett, Mihye Kwon, Samuel Whittle, Catherine Hill   +4 more
wiley   +1 more source

Leveraging Design of Experiments to Unravel the Amplification Mechanism of Single‐Molecule Wide‐Field Biosensors

Advanced Materials Interfaces, EarlyView.
Detecting single molecules on large interfaces is challenging due to minimal perturbations on the sensing surface. Some biological systems achieve this feat using amplification mechanisms, but their molecular foundations remain unclear. To investigate, a Design of Experiments (DoE) approach examines how pH and ionic strength in conditioning solutions ...
Michele Catacchio, Mariapia Caputo, Lucia Sarcina, Cinzia Di Franco, Matteo Piscitelli, Erika Castrignanò, Paolo Bollella, Gaetano Scamarcio, Eleonora Macchia, Luisa Torsi   +9 more
wiley   +1 more source

Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease [PDF]

, 2014
Background Crohn’s disease (CD) is a chronic relapsing inflammatory condition. Many patients fail to achieve remission with medical management and require surgical interventions.
Angelberger, Angelberger, Ardizzone, Armuzzi, Armuzzi, Armuzzi, Benchimol, Bernell, Colonna, D'Haens, D'Haens, Dilger, Doherty, Ferrante, Gordon, Guyatt, Hafraoui, Hanauer, Hanauer, Herfarth, Herfarth, Higgins, Higgins, Korelitz, Manosa, Mañosa, Nos, Pitkin, Prefontaine, Regueiro, Reinisch, Reinisch, Reinisch, Reinisch, Rolfe, Rutgeerts, Savarino, Savarino, Savarino, Schünemann, Steinhart, Williams   +41 more
core   +1 more source

Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis

BMC Gastroenterology, 2022
Background and aims There are limited comparative data for infliximab and vedolizumab in inflammatory bowel disease patients. Methods We conducted a systematic review and meta-analysis to compare the efficacy and safety of infliximab and vedolizumab in ...
Laurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, Silvio Danese, Jordi Guardiola, Jørgen Jahnsen, Charles Lees, Edouard Louis, Milan Lukáš, Walter Reinisch, Xavier Roblin, Minyoung Jang, Han Geul Byun, Dong-Hyeon Kim, Sung Jeong Lee, Raja Atreya   +15 more
doaj   +1 more source